FDA and US Centers for Disease Control and Prevention (CDC) has reaffirmed that Merck’s GARDASIL continues to be safe and effective, and its benefits continue to outweigh its risks.
Merck said that GARDASIL is for use in girls and women 9 to 26 years of age, for the prevention of cervical, vulvar, and vaginal cancers, precancerous or dysplastic lesions, and genital warts caused by HPV Types 6, 11, 16, and 18.
Richard Haupt, head of GARDASIL clinical program, said: We will continue our practice of effectively communicating the safety profile of GARDASIL, it’s a responsibility Merck takes very seriously.
Parents should understand the extensive data supporting the safety profile of this vaccine, and we encourage them to look to CDC and FDA, and to the advice of their own physicians, to make an informed choice about something as important as a vaccine to help prevent cervical cancer, he added.